• 제목/요약/키워드: Gastric cancer tissue

검색결과 159건 처리시간 0.023초

Prognostic and Clinicopathological Significance of Transducer-Like Enhancer of Split 1 Expression in Gastric Cancer

  • Lee, Ji-Hye;Son, Myoung-Won;Kim, Kyung-Ju;Oh, Mee-Hye;Cho, Hyundeuk;Lee, Hyun Ju;Jang, Si-Hyong;Lee, Moon Soo
    • Journal of Gastric Cancer
    • /
    • 제16권1호
    • /
    • pp.21-27
    • /
    • 2016
  • Purpose: Transducer-like enhancer of split 1 (TLE1) is a member of the Groucho/TLE family of transcriptional co-repressors that regulate the transcriptional activity of numerous genes. TLE1 is involved in the tumorigenesis of various tumors. We investigated the prognostic significance of TLE1 expression and its association with clinicopathological parameters in gastric cancer (GC) patients. Materials and Methods: Immunohistochemical analysis of six tissue microarrays was performed to examine TLE1 expression using 291 surgically resected GC specimens from the Soonchunhyang University Cheonan Hospital between July 2006 and December 2009. Results: In the non-neoplastic gastric mucosa, TLE1 expression was negative. In GC, 121 patients (41.6%) were positive for TLE1. The expression of TLE1 was significantly associated with male gender (P=0.021), less frequent lymphatic (P=0.017) or perineural invasion (P=0.029), intestinal type according to the Lauren classification (P=0.024), good histologic grade (P<0.001), early pathologic T-stage (P=0.012), and early American Joint Committee on Cancer stage (P=0.022). In the Kaplan-Meier analysis, the TLE1 expression was significantly associated with longer disease-free (P=0.022) and overall (P=0.001) survival rates. Conclusions: We suggested that TLE1 expression is a good prognostic indicator in GCs.

위암 환자에서 p53과 HSP27의 임상병리학적 의의 (Clinicopathological Significance of p53 and HSP27 in Gastric-cancer Patients)

  • 이하균;권성준;백승삼
    • Journal of Gastric Cancer
    • /
    • 제4권3호
    • /
    • pp.169-175
    • /
    • 2004
  • Purpose: The tumor suppressor gene p53 has been shown to be a factor in the carcinogenesis or progression of gastric cancer. The mutant p53 has been reported to cause a higher risk of lymph-node metastasis. Futhermore, mutation of the p53 has been linked to a poor prognosis for gastric cancer. The heat shock protein-27 (HSP27), a stress protein, has also been reported to be a poor prognostic factor in ovarian and breast cancers. However, in gastric-cancer patients, controversies exist as to its influence on the prognosis. In the present study, we used an immunohistochemical stain to observe the effects of p53 and HSP27 on the clinicopathological factors and on the prognosis for gastric-cancer patients. Materials and Methods: To evaluate the significance of p53 and HSP27 in gastric cancer patients, we analyzed 212 cases of gastric cancer (stage I.IV). Tissue samples of 212 patients were stained immunohistochemically for the mutant p53 protein and for HSP27. The correlations between protein expression and the clinicopathological factors were investigated. Results: The overall expression rates for p53 and HSP27 were $36.9\%\;and\;27.8\%$, respectively. p53 and HSP27 were correlated to each other because the HSP27 expression rate was higher in the p53-positive group (P=0.046). Statistically, the p53 and the HSP27 expression rates were significantly increased in the case of tumor invasiveness, lymphatic metastasis and vessel involvement. Therefore, they play a role in cancer progression. The 5-year survival rates of the p53-positive and the p53-negative groups were $62.8\%\;and\;60.1\%$, respectively (P=0.793) while the 5-year survival rates for the HSP27-positive and HSP27-negative groups were $54.2\%\;and\;63.1\%$, respectively (P=0.090). Conclusion: p53 and HSP27 were correlated to each other in our immunohistochemical study of gastric carcinomas and they were not independent prognostic factors in gastric- cancer patients. However, further studies are needed to determine their prognostic values for gastric-cancer patients.

  • PDF

Expression of Cytoplasmic 8-oxo-Gsn and MTH1 Correlates with Pathological Grading in Human Gastric Cancer

  • Song, Wen-Jie;Jiang, Ping;Cai, Jian-Ping;Zheng, Zhi-Qiang
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권15호
    • /
    • pp.6335-6338
    • /
    • 2015
  • Background: Cancers have dysfunctional redox regulation resulting in production of reactive oxygen species (ROS), damaging DNA, RNA and free NTPs, and causing the accumulation of oxidative nucleic acids in cytoplasm. The major types are 8-oxo-7,8-dihydroguanine(8-oxoGsn) in RNA and 8-oxo-7,8-dihydro-2' deoxyguanosine(8-oxodGsn) in Mt-DNA. The MTH1 protein sanitizes oxidized nucleotide pools from NTPs to monophosphates, preventing the occurrence of transversion mutations. This study concerned cytoplasmic 8-oxodGsn/Gsn and MTH1 expression in gastric cancer and para-cancer tissues and elucidated roles of nucleic-acid oxidation and anti-oxidation. Materials and Methods: A polymer HRP detection system was used to detect 8-oxo-Gsn/dGsn and MTH1 expression in 51 gastric cancer and para-cancer tissue samples. Analyses of patient clinical and pathological data were also performed. Results: The expression of MTH1 and the 8-oxo-dGsn/Gsn ratio were significantly higher in cancer tissues than para-cancer tissues (P<0.05). Cytoplasmic 8-oxo-Gsn and MTH1 were both found to positively correlate (P<0.05) with tumor differentiation, while no significant associations were found with gender, age, invasion depth, lymph node metastasis and clinical stage (P>0.05). Conclusions: We found 8-oxo-dGsn/Gsn and MTH1 are both highly expressed in gastric cancer tissues, especially in well differentiated lesions. In addition, oxidated mtDNA is prevalently expressed in gastric cancers, while 8-oxo-Gsn expression in cytoplasmic RNA is a bit lower, but more selectively.

위암에서 $PPAR-{\gamma}$ 발현의 임상적 의의 (Expression of the Peroxisome-proliferator-activated $Receptor-{\gamma}$ in Human Gastric Cancer)

  • 조동희;강성구;박상수;윤진;김일명;윤성민;이윤경;이용직;양대현;조익행;신동규
    • Journal of Gastric Cancer
    • /
    • 제6권4호
    • /
    • pp.250-256
    • /
    • 2006
  • 목적: 최근 Peroxisome-proliferator-activated receptors (PPAR) 의 역할에 대한 관심이 고조되고 있으나 위암에 대한 실제 임상연구는 부족한 실정이다. 이에 저자들은 위암 조직에서의 $PPAR-{\gamma}$의 발현율과 임상적 의의에 대해 분석을 시행하였다. 대상 및 방법: 2001년 1월부터 2005년 12월까지 서울의료원에서 위암으로 근치적수술을 시행 받은 128명을 대상으로 하였다. 적출된 위조직으로 만들어진 파라핀 블록을 이용해 위암조직 125예와 위암주변 정상조직 128예를 채취하여 $PPAR-{\gamma}$ 발현을 면역조직화학염색으로 확인한 후 비교 분석하였다. 결과: 대상 환자의 평균 연령은 61세였으며 남자 84명 (65.6%), 여자 44명(34.4%)으로 1.9 : 1이었다. $PPAR-{\gamma}$ 발현의 양성률은 정상조직 73/128명(57.0%)에 비하여 위암조직에서는 104/128명(81.3%)으로 유의하게 높았다(P<0.001). 위암조직의 분화도에 따른 $PPAR-{\gamma}$ 발현의 차이에서 분화도가 양호한 경우의 양성률(87.0%)에 비해 나쁜 경우 발현율(74.6%)이 낮았으나 통계적 유의성은 없었다(P=0.074). 위암조직에서와 $PPAR-{\gamma}$ 발현 유무와 생존율 사이에 통계적 유의성은 없었으나(P=0.377) 정상조직에서 $PPAR-{\gamma}$의 발현은 단변량 분석에서 유의하게 높은 생존율을 보였다(P=0.003). 5년 생존율과 연관지어 다변량 분석 통계에서 의미가 있었던 것은 UICC TNM 병기뿐이었다(P<0.001). TNM 병기별 5년 생존율은 IA-89.9%, IB-90.0%, II-89.7%, IIIA-41.0%, IIIB-25.9%, IV-14.6% 였다. 결론: 위암조직에서 정상조직에 비하여 $PPAR-{\gamma}$ 발현이 유의하게 높았으며 위암조직의 분화도가 좋을수록 발현율이 높았다. $PPAR-{\gamma}$의 정상조직 내 발현이 단변량 분석상 유의한 생존율 향상이 있었지만 다변량 분석에서는 유의성이 없어 향후 이에 대한 좀더 많은 증례로 유의성을 찾는 연구가 필요할 것으로 생각된다.

  • PDF

Expression of Peroxisome Proliferator-Activated Receptor Gamma in Helicobacter Pylori-associated Mouse Gastric Cancer Tissue and Human Gastric Epithelial Cells.

  • Oh, Sang-yeon;Nam, Ki-taek;Jang, Dong-deuk;Yang, Ki-hwa;Hahm, Ki-baik;Kim, Dae-yong
    • 한국수의병리학회:학술대회논문집
    • /
    • 한국수의병리학회 2003년도 추계학술대회초록집
    • /
    • pp.11-11
    • /
    • 2003
  • Peroxisome proliferator-activated receptor (PPAR) is nuclear hormone receptors that can be activated by a variety of compounds. Two PPAR gamma isoforms are expressed at the protein level in mouse, gamma 1 and gamma 2. And PPAR gamma is intimately associated with cell differentiation and proliferation[1]. So aim of this study, investigated where express PPAR gamma in mouse gastric cancer tissues, including human gastric cancer cell lines and expression pattern of PPAR gamma. (omitted)

  • PDF

In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer

  • Park, Seul-Kee;Woo, Yang-Hee;Kim, Ho-Geun;Lee, Yong-Chan;Choi, Sung-Ho;Hyung, Woo-Jin;Noh, Sung-Hoon
    • Journal of Gastric Cancer
    • /
    • 제10권4호
    • /
    • pp.155-161
    • /
    • 2010
  • Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

Loss of FAT Atypical Cadherin 4 Expression Is Associated with High Pathologic T Stage in Radically Resected Gastric Cancer

  • Jung, Hae Yoen;Cho, Hyundeuk;Oh, Mee-Hye;Lee, Ji-Hye;Lee, Hyun Ju;Jang, Si-Hyong;Lee, Moon Soo
    • Journal of Gastric Cancer
    • /
    • 제15권1호
    • /
    • pp.39-45
    • /
    • 2015
  • Purpose: Recent studies have revealed recurrent alterations in the cell adhesion gene FAT4, a candidate tumor suppressor gene, in cancer. FAT atypical cadherin 4 (FAT4) is a transmembrane receptor involved in the Hippo signaling pathway, which is involved in the control of organ size. Here, we investigated the loss of FAT4 expression and its association with clinicopathological risk factors in gastric cancer. Materials and Methods: We assessed the expression of FAT4 by using immunohistochemistry on three tissue microarrays containing samples from 136 gastric cancer cases, radically resected in the Soonchunhyang University Cheonan Hospital between July 2006 and June 2008. Cytoplasmic immunoexpression of FAT4 was semi-quantitatively scored using the H-score system. An H-score of ${\geq}10$ was considered positive for FAT4 expression. Results: Variable cytoplasmic expressions of FAT4 were observed in gastric cancers, with 33 cases (24.3%) showing loss of expression (H-score <10). Loss of FAT4 expression was associated with an increased rate of perineural invasion (H-score <10 vs. ${\geq}10$, 36.4% vs. 16.5%, P=0.015), high pathologic T stage (P=0.015), high tumor-node-metastasis stage (P=0.017), and reduced disease-free survival time (H-score <10 vs. ${\geq}10$, mean survival $62.7{\pm}7.3$ months vs. $79.1{\pm}3.1$ months, P=0.025). However, no association was found between the loss of FAT4 expression and tumor size, gross type, histologic subtype, Lauren classification, lymphovascular invasion, or overall survival. Conclusions: Loss of FAT4 expression appears to be associated with invasiveness in gastric cancer.

위암에시 PET의 임상적 역할 (Role of PET Scan in Gastric Cancer as a Diagnostic Tool)

  • 천기정;김병일;임상무
    • 대한위암학회:학술대회논문집
    • /
    • 대한위암학회 2002년도 제14회 추계학술대회
    • /
    • pp.24-33
    • /
    • 2002
  • Clinical application of positron emission tomography (PET) is rapidly increasing for the detection and staging of cancer at whole-body studies performed with the glucose analogue tracer 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). Although FDG PET cannot match the anatomic resolution of conventional imaging techniques in gastrointestinal and abdominal organs, it is particularly useful for identification and characterization of whole body at the same time. FDG PET can show foci of metastatic disease that may not be apparent at conventional anatomic imaging and can aid in the characterization of indeterminate soft-tissue masses. Most gastrointestinal cancer need to surgical management. FDG PET can improve the selection of patients for surgical treatment and thereby reduce the morbidity and mortality associated with inappropriate surgery. FDG PET is also useful for the early detection of recurrence and the monitoring of therapeutic effect. The gastrointestinal cancers, such as gastroeso-phageal cancer, colorectal cancer, liver cancer and pancreatic cancer, are common malignancies in Korea. PET is one of the most promising and useful methodology for the management of gastric cancer as well as other gastrointestinal cancers.

  • PDF

Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma: dosimetric comparison and risk assessment of solid secondary cancer

  • Bae, Sun Hyun;Kim, Dong Wook;Kim, Mi-Sook;Shin, Myung-Hee;Park, Hee Chul;Lim, Do Hoon
    • Radiation Oncology Journal
    • /
    • 제35권1호
    • /
    • pp.78-89
    • /
    • 2017
  • Purpose: To determine the optimal radiotherapy technique for gastric mucosa-associated lymphoid tissue lymphoma (MALToma), we compared the dosimetric parameters and the risk of solid secondary cancer from scattered doses among anterior-posterior/ posterior-anterior parallel-opposed fields (AP/PA), anterior, posterior, right, and left lateral fields (4_field), 3-dimensional conformal radiotherapy (3D-CRT) using noncoplanar beams, and intensity-modulated radiotherapy composed of 7 coplanar beams (IMRT_co) and 7 coplanar and noncoplanar beams (IMRT_non). Materials and Methods: We retrospectively generated 5 planning techniques for 5 patients with gastric MALToma. Homogeneity index (HI), conformity index (CI), and mean doses of the kidney and liver were calculated from the dose-volume histograms. Applied the Biological Effects of Ionizing Radiation VII report to scattered doses, the lifetime attributable risk (LAR) was calculated to estimate the risk of solid secondary cancer. Results: The best value of CI was obtained with IMRT, although the HI varied among patients. The mean kidney dose was the highest with AP/PA, followed by 4_field, 3D-CRT, IMRT_co, and IMRT_non. On the other hand, the mean liver dose was the highest with 4_field and the lowest with AP/PA. Compared with 4_field, the LAR for 3D-CRT decreased except the lungs, and the LAR for IMRT_co and IMRT_non increased except the lungs. However, the absolute differences were much lower than <1%. Conclusion: Tailored RT techniques seem to be beneficial because it could achieve adjacent organ sparing with very small and clinically irrelevant increase of secondary solid cancer risk compared to the conventional techniques.